Search results for "Bone pain"

showing 5 items of 15 documents

Spinal neuronal correlates of tapentadol analgesia in cancer pain: A back-translational approach

2014

Background Pain is a common and highly debilitating complication for cancer patients significantly compromising their quality of life. Cancer-induced bone pain involves a complex interplay of multiple mechanisms including both inflammatory and neuropathic processes and also some unique changes. Strong opioids are a mainstay of treatments but side effects are problematic and can compromise optimal pain control. Tapentadol is a novel dual-action drug, both stimulating inhibitory μ-opioid receptors (MOR) and mediating noradrenaline reuptake inhibition (NRI) leading to activation of the inhibitory α-2 adrenoceptor. It has been demonstrated to treat effectively both acute and chronic pain. We he…

business.industryChronic painAtipamezole(+)-NaloxonePharmacologyTapentadolmedicine.disease3. Good healthAnesthesiology and Pain MedicineOpioidMedicinePremovement neuronal activitymedicine.symptombusinessBone painCancer painmedicine.drugEuropean Journal of Pain
researchProduct

Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study

2003

OBJECTIVE To present the long-term outcome of patients with locally advanced or metastatic prostate carcinoma treated by first-line antiandrogen monotherapy. PATIENTS AND METHODS From 1983 to 1990, 41 patients with advanced prostate carcinoma were treated with flutamide monotherapy until progression or the appearance of toxicity. Twenty-five patients (61%) had T3-T4N0M0 and 16 (39%) T2–4N0–3M1 prostate carcinoma. Consensus criteria were adopted to evaluate the response. Plasma testosterone and sexual function were recorded for the first 3 years. RESULTS Flutamide was administered for up to 147 months; seven patients (17%) interrupted the treatment because of toxicity. There was an objective…

medicine.medical_specialtyPerformance statusmedicine.drug_classbusiness.industryUrologyUrologyAntiandrogenmedicine.diseaseSurgeryFlutamideProstate-specific antigenchemistry.chemical_compoundProstate cancerchemistrymedicineCarcinomaHormonal therapymedicine.symptomBone painbusinessBJU International
researchProduct

Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis w…

2019

Background: The gain-of function mutation KIT D816V plays a central role in the pathogenesis of systemic mastocytosis (SM). Among subtypes of SM, indolent SM (ISM) is the most frequent and is associated with normal/near-normal life expectancy; smoldering SM (SSM) is a subtype with a relatively higher burden of mast cells and may be associated with an increased risk of progression to advanced mastocytosis. However, both ISM and SSM patients may experience severe symptoms associated with mast cell mediator release, such as pruritus, diarrhea, anaphylaxis, and bone pain, which can be severely debilitating and have a profoundly negative impact on quality of life. Symptomatic treatments (eg, ant…

medicine.medical_specialtybusiness.industrySurrogate endpointImmunologyPhases of clinical researchCell BiologyHematologymedicine.diseasePlaceboBiochemistryDouble blindInternal medicineMedicineIn patientSystemic mastocytosismedicine.symptombusinessBone painAsthmaBlood
researchProduct

Mucopolysaccharidoses and other lysosomal storage diseases.

2013

Mucopolysaccharidosis and other lysosomal storage diseases are rare, chronic, and progressive inherited diseases caused by a deficit of lysosomal enzymes. Patients are affected by a wide variety of symptoms. For some lysosomal storage diseases, effective treatments to arrest disease progression, or slow the pathologic process, and increase patient life expectancy are available or being developed. Timely diagnosis is crucial. Rheumatologists, orthopedics, and neurologists are commonly consulted due to unspecific musculoskeletal signs and symptoms. Pain, stiffness, contractures of joints in absence of clinical signs of inflammation, bone pain or abnormalities, osteopenia, osteonecrosis, secon…

musculoskeletal diseasesmedicine.medical_specialtyPathologyMucopolysaccharidosisPainOsteochondrodysplasiasHip dysplasia (canine)RheumatologyInternal medicineLysosomal storage diseasemedicineHumansMusculoskeletal DiseasesBone painHip Dislocation CongenitalMuscle contractureHip Contracturebusiness.industryOsteonecrosisMucopolysaccharidosesPrognosismedicine.diseaseOsteopeniaBone Diseases MetabolicEarly DiagnosisHip ContractureOrthopedic surgeryHip JointJointsJoint Diseasesmedicine.symptomLysosomesbusiness
researchProduct

MDS-191: Long-Term Efficacy and Safety of Luspatercept in Lower-Risk Myelodysplastic Syndromes (MDS): Phase 2 PACE-MDS Study

2020

Background: Luspatercept, a first-in-class erythroid maturation agent, has been investigated in patients with LR-MDS and ring sideroblasts (RS) (MEDALIST; Fenaux and Platzbecker NEJM 2020) and in an ongoing Phase 3 trial regardless of RS status (COMMANDS, NCT03682536 ). The previously reported Phase 2 trial of luspatercept (Platzbecker Lanc Onc 2017) includes subtypes of LR-MDS with and without RS, regardless of prior ESA exposure, and various EPO levels. Aims: Evaluate the long-term safety and efficacy of luspatercept in LR-MDS. Methods: Patients were IPSS low/int-1, age ≥ 18 years, Hgb NCT01749514 ; NCT02268383 ). Results: As of 13July2019, 115 patients were enrolled, of whom 108 were tre…

myalgiaCancer Researchmedicine.medical_specialtyErythemabusiness.industryMyelodysplastic syndromesPeripheral edemaPhases of clinical researchHematologymedicine.diseaseLower riskClinical trialOncologyhemic and lymphatic diseasesInternal medicinemedicinemedicine.symptomBone painbusinessClinical Lymphoma Myeloma and Leukemia
researchProduct